Segall Bryant & Hamill LLC Sells 2,068 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Segall Bryant & Hamill LLC lowered its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 1.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 153,988 shares of the company’s stock after selling 2,068 shares during the period. Segall Bryant & Hamill LLC owned 0.12% of Vaxcyte worth $12,605,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in PCVX. Diversified Trust Co bought a new stake in Vaxcyte during the fourth quarter worth $1,433,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Vaxcyte by 23.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company’s stock worth $2,163,000 after purchasing an additional 4,962 shares during the last quarter. Citigroup Inc. raised its holdings in shares of Vaxcyte by 33.0% in the 3rd quarter. Citigroup Inc. now owns 220,543 shares of the company’s stock valued at $25,201,000 after purchasing an additional 54,748 shares during the period. TimesSquare Capital Management LLC lifted its stake in Vaxcyte by 53.7% in the 4th quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company’s stock valued at $33,860,000 after purchasing an additional 144,516 shares during the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Vaxcyte by 186.2% during the third quarter. Principal Financial Group Inc. now owns 52,702 shares of the company’s stock worth $6,022,000 after purchasing an additional 34,287 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Stock Performance

PCVX opened at $71.90 on Wednesday. The stock has a fifty day moving average of $81.14 and a 200-day moving average of $93.33. The company has a market capitalization of $9.26 billion, a P/E ratio of -15.63 and a beta of 1.02. Vaxcyte, Inc. has a fifty-two week low of $58.10 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.14. On average, equities research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Insider Transactions at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total transaction of $586,160.00. Following the transaction, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Teri Loxam sold 6,250 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now owns 7,175 shares of the company’s stock, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,250 shares of company stock valued at $3,840,018. 3.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

PCVX has been the topic of several research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, February 26th. The Goldman Sachs Group initiated coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price target on the stock. Finally, Guggenheim reaffirmed a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte has a consensus rating of “Buy” and an average price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.